[go: up one dir, main page]

EP1030679A4 - Zusammenstellungen und Verfahren zur verbesserten Internalisierung und Abbau von Urokinase-Typ Plasminogen Aktivator - Google Patents

Zusammenstellungen und Verfahren zur verbesserten Internalisierung und Abbau von Urokinase-Typ Plasminogen Aktivator

Info

Publication number
EP1030679A4
EP1030679A4 EP98957325A EP98957325A EP1030679A4 EP 1030679 A4 EP1030679 A4 EP 1030679A4 EP 98957325 A EP98957325 A EP 98957325A EP 98957325 A EP98957325 A EP 98957325A EP 1030679 A4 EP1030679 A4 EP 1030679A4
Authority
EP
European Patent Office
Prior art keywords
internalization
promoting
degradation
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98957325A
Other languages
English (en)
French (fr)
Other versions
EP1030679A1 (de
Inventor
Douglas Cines
Abd Al-Roof Higazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP1030679A1 publication Critical patent/EP1030679A1/de
Publication of EP1030679A4 publication Critical patent/EP1030679A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP98957325A 1997-10-17 1998-10-15 Zusammenstellungen und Verfahren zur verbesserten Internalisierung und Abbau von Urokinase-Typ Plasminogen Aktivator Withdrawn EP1030679A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6227497P 1997-10-17 1997-10-17
US62274P 1997-10-17
PCT/US1998/021800 WO1999020295A1 (en) 1997-10-17 1998-10-15 Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator

Publications (2)

Publication Number Publication Date
EP1030679A1 EP1030679A1 (de) 2000-08-30
EP1030679A4 true EP1030679A4 (de) 2003-03-05

Family

ID=22041403

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98957325A Withdrawn EP1030679A4 (de) 1997-10-17 1998-10-15 Zusammenstellungen und Verfahren zur verbesserten Internalisierung und Abbau von Urokinase-Typ Plasminogen Aktivator

Country Status (5)

Country Link
EP (1) EP1030679A4 (de)
JP (1) JP2001520200A (de)
AU (1) AU739373B2 (de)
CA (1) CA2306953A1 (de)
WO (1) WO1999020295A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216847A1 (en) * 2000-10-26 2002-05-06 K.U. Leuven Research And Development Epitopes of pai-1
US20030211095A1 (en) * 2002-05-08 2003-11-13 Abd. Al-Roof Higazi Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
US7271143B1 (en) * 2001-07-10 2007-09-18 Thrombotech Ltd. Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
DK2173371T3 (da) * 2007-07-24 2012-02-06 Thrombotech Ltd Peptider afledt af plasminogenaktivatorinhibitor-1 og anvendelser deraf

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320840A2 (de) * 1987-12-18 1989-06-21 BEHRINGWERKE Aktiengesellschaft Peptide, Verfahren zu ihrer Herstellung, ihre Verwendung zur Gewinnung von Antikörpern sowie deren Verwendung zur Blockierung der PAI-1-Aktivität menschlichen Blutes
WO1994028145A2 (en) * 1993-06-01 1994-12-08 Chiron Corporation Expression of urokinase plasminogen activator inhibitors
WO1995002413A1 (en) * 1993-07-16 1995-01-26 Cancerforskningsfondet Af 1989 Suppression of inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
ZA928954B (en) * 1991-12-24 1993-05-19 Akzo Nv Peptides immunochemically reactive with antibodies directed against hepatitis non-A, non-B virus.
US5674078A (en) * 1996-01-23 1997-10-07 The Whitaker Corporation Multi-directional interface header assembly

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320840A2 (de) * 1987-12-18 1989-06-21 BEHRINGWERKE Aktiengesellschaft Peptide, Verfahren zu ihrer Herstellung, ihre Verwendung zur Gewinnung von Antikörpern sowie deren Verwendung zur Blockierung der PAI-1-Aktivität menschlichen Blutes
WO1994028145A2 (en) * 1993-06-01 1994-12-08 Chiron Corporation Expression of urokinase plasminogen activator inhibitors
WO1995002413A1 (en) * 1993-07-16 1995-01-26 Cancerforskningsfondet Af 1989 Suppression of inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AL-ROOF HIGAZI A ET AL: "SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR BOUND TO ITS RECEPTOR IS RELATIVELY RESISTANT TO PLASMINOGEN ACTIVATOR INHIBITORTYPE 1", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 87, no. 9, 1 May 1996 (1996-05-01), pages 3545 - 3549, XP001037493, ISSN: 0006-4971 *
See also references of WO9920295A1 *

Also Published As

Publication number Publication date
AU739373B2 (en) 2001-10-11
CA2306953A1 (en) 1999-04-29
JP2001520200A (ja) 2001-10-30
AU1360999A (en) 1999-05-10
EP1030679A1 (de) 2000-08-30
WO1999020295A1 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
EP1152764A4 (de) Zusammenstellungen und methoden zur verwendung in der zielung der vaskularen zerstörung
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
ID24592A (id) Metoda dan komposisi-komposisi untuk pemutihan gigi
ID26994A (id) Glukonolakton dan glukarolakton sebagai anti-iritasi pada komposisi-komposisi kosmetik
MXPA01000174A (es) Materiales y metodos para la alteracion de los niveles de enzimas y de acetil-coa en plantas.
EP1023017A4 (de) Fibrinkleber ohne fibrinogen sowie "bio-verschliessende" mittel und methoden
NL300395I2 (nl) GnRH antagonisten gemodificeerd in posities 5 en 6
AU1453200A (en) Cyclic peptide ligands that target urokinase plasminogen activator receptor, their pharmaceutical compositions and use
EP0797447A4 (de) Heterozyklische pentapeptitische und halophenyl amide als hemmer für menschlichen krebs
DE69638351D1 (de) Sowie zur resektion des distalen und vorderen femurs
DE69607321D1 (de) Reinigungsverfahren und zusammensetzung
IS5836A (is) Stöðugar vökvasamsetningar úr bótulín eiturefni
AU3374795A (en) Conjugates of vascular endothelial growth factor with targeted agents
EP0912549A4 (de) Verbindungen und verfahren zur bereitstellung aktiver zubereitungen und deren verwendung
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
DE69716580D1 (de) Polysaccharidderivate und hydraulische zusammensetzungen
ATE280213T1 (de) Waschemittelzusammensetzungen mit proteasen und verbesserten amylasen
NZ297118A (en) Antithrombotic formulation; comprises thrombin inhibitor and one or more absorption enhancing agents
PL339429A1 (en) Urokinase inhibitors
DZ2333A1 (fr) Conjugues utiles au traitement du cancer de la prostate
DE69836329D1 (de) Schneller und hochverstärkender operationsverstärker
EP1030679A4 (de) Zusammenstellungen und Verfahren zur verbesserten Internalisierung und Abbau von Urokinase-Typ Plasminogen Aktivator
DE69708418D1 (de) Naphthylverbindungen und Zusammensetzungen
HUP0100781A3 (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia and pharmaceutical compositions containing them
MA26540A1 (fr) Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/08 A, 7A 61K 38/10 B, 7A 61K 38/16 B, 7A 61P 35/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20041022